|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Using the population based San Francisco Adult Glioma study, we evaluated associations between XRCC1 Arg399Gln, MGMT Leu84Phe, and MGMT Ile143Val polymorphisms with glioma risk among white cases (n = 441 to 453) and controls (n = 487 to 526).
|
17898525 |
2007 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, transferrin nanoparticles encapsulating temozolomide have the potential of a promising anti-tumor strategy against glioma of the O6-methylguanine-DNA-methyltransferase gene promoter methylation.
|
29088799 |
2017 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Interestingly, the risk for glioma was dramatically increased in ionizing radiation exposure individuals who had the wild-type genotypes of MGMT F84L and PARP1 A762V (adjusted odds ratios, 5.95; 95% confidence intervals, 2.21-16.65).
|
19124499 |
2009 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that glioma susceptibility is associated with rs1799782 and rs25487 of X-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1), rs1805377 of XRCC4, rs1800067 of excision repair cross-complementing rodent repair deficiency complementation group 4 (ERCC4) and rs3212986 of ERCC1 in Asian population, and rs12917 of O-6-methylguanine-DNA methyltransferase (MGMT) and rs1136410 of poly(ADP-ribose) polymerase 1 (PARP1) in Caucasian population.
|
27055523 |
2017 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas.
|
17721049 |
2007 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Detection of IDH1 mutations and the status of MGMT promoter on intraoperative fresh tissue section from frameless neuronavigation needle biopsy. Analysis on 17 patients with brain glial tumor ineligible for craniotomy and tumor resection.
|
21781445 |
2013 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, the risk for glioma was dramatically increased in ionizing radiation exposure individuals who had the wild-type genotypes of MGMT F84L and PARP1 A762V (adjusted odds ratios, 5.95; 95% confidence intervals, 2.21-16.65).
|
19124499 |
2009 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.
|
28436299 |
2017 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Algorithms have been developed to detect the glioma CpG island methylator phenotype (G-CIMP) associated with IDH1/2 mutation, 1p/19q codeletion, and MGMT promoter methylation using a single assay.
|
25028501 |
2014 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Three of these markers - 1p/19q deletions, MGMT methylation status, and mutations in the IDH1 gene - are so potent that a new brain tumor subtype, the "triple negative" glioma (1p/19q intact, MGMT unmethylated, IDH1 non-mutated) has entered common parlance.
|
23288644 |
2013 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study provides evidence that DNA repair genes ERCC1, ERCC2, and XRCC1 might be low-penetrance glioma-risk genes, while MGMT and PARP1 polymorphisms may confer protection against glioma.
|
24500421 |
2014 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Sixty three cases of glioma were evaluated for MGMT promoter methylation by methylation-specific PCR (MS-PCR) and protein expression by immunostaining (IHC).
|
29712977 |
2018 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activated leukocyte adhesion molecule expression in gliomas was independent of proliferative activity, MGMT status, patient survival, and age, whereas gliomas with IDH1 (R132H) mutation had significantly higher activated leukocyte adhesion molecule levels than their wild-type counterparts.
|
22304788 |
2012 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the effect of typical polymorphisms of MTHFR (C677T and A1298C) on MGMT methylation based on different serum folate levels in patients with glioma from Northeast China.
|
24301776 |
2013 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MGMT CpG heterogeneity was investigated in 213 glioma patients in two tested cohorts: cohort A in which CpGs 75-82 were tested and cohort B in which CpGs 72-78 were tested.
|
30291347 |
2019 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Southern analysis of EcoRI-digested DNA probed with MGMT cDNA revealed no amplification, rearrangement or deletions of the MGMT gene in any of the glioma cell lines.
|
1893534 |
1991 |
|
Glioma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The dose-intensified BG and BCNU therapy produced significant growth delays of glioma xenografts in MGMT-P140K-transplanted mice, extending the tumor doubling time by >40 days.
|
14707273 |
2003 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The positive rate of MGMT autoantibody to 20 peptides in glioma groups is compared with healthy individuals, the positive rate of MGMT-02 (45%), MGMT-04 (27%), MGMT-07 (21%), MGMT-10 (13%), and MGMT-18 (24%) were significantly elevated in patients with glioma.
|
31210005 |
2019 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<i>FoxD2-AS1</i> is a prognostic factor in glioma and promotes temozolomide resistance in a O<sup>6</sup>-methylguanine-DNA methyltransferase-dependent manner.
|
31680769 |
2019 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Active MGMT might have a protective role in LGG tumors, enabling evolution to severe malignancy.
|
28575062 |
2017 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although methylguanine-DNA-methyltransferase (MGMT) plays an important role in resistance to temozolomide (TMZ) in glioma, 40% of gliomas with MGMT inactivation are still resistant to TMZ.The underlying mechanism is not clear.
|
28185110 |
2017 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
O6-Methylguanine-DNA methyltransferase (MGMT), a DNA repair protein, is one of the implicated factors in glioma chemoresistance.
|
16033832 |
2005 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, future clinical trials will need to determine, for each subtype of glioma, the degree to which MGMT promoter methylation is predictive or prognostic, and whether testing should become routine clinical practice.
|
19997073 |
2010 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Drug-resistance genes messenger ribonucleic acid (mRNA) expressions were investigated in drug-resistant human glioma cell lines derived from U87MG and 46 frozen samples of retrospectively examined neuroepithelial tumors (12 low grade neuroepithelial tumors, 16 Grade III gliomas, 11 glioblastomas, and 7 other malignant neuroepithelial tumors such as medulloblastomas and primitive neuroectodermal tumors) by RT-PCR with the specific primers for O6-methylguanine DNA methyltransferase (MGMT), multidrug-resistance gene 1 (MDR1), multidrug-resistance-associated protein (MRP), and glutathione-S-transferase-pi (GST-pi).
|
10894369 |
2000 |
|
Glioma
|
0.400 |
Biomarker
|
disease |
BEFREE |
No single method of MGMT analysis has emerged as a clear choice for routine clinical testing of MGMT in glioma patients.
|
22986811 |
2012 |